LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L
Lucia Taraborrelli, Nieves Peltzer, Antonella Montinaro, Sebastian Kupka, Eva Rieser, Torsten Hartwig, Aida Sarr, Maurice Darding, Peter Draber, Tobias L Haas, Ayse Akarca, Teresa Marafioti, Manolis Pasparakis, John Bertin, Peter J Gough, Philippe Bouillet, Andreas Strasser, Martin Leverkus, John Silke, Henning Walczak
Nature Communications | NATURE PUBLISHING GROUP | Published : 2018
Awarded by Wellcome Trust
Awarded by ERC
Awarded by NHMRC
Awarded by Swiss National Science Foundation
We thank Dr Geert van Loo (VIB Inflammation Research Center, Gent, Belgium) for providing K14Cre mice; Dr Vishva Dixit and Dr Kim Newton (Genentech, Inc., South San Francisco, CA) for providing Ripk3<SUP>KO</SUP> mice; Dr Razq Hakem (University of Toronto, Ontario) for Casp8<SUP>KO</SUP> mice; Helena Draberova, Paul Levy and his staff at the Kathleen Lonsdale Building (UCL, London, UK) for technical assistance; and Lorraine Lawrence (NHLI, Imperial College, London, UK) for histology service. This work was funded by a Wellcome Trust Senior Investigator Award (096831/Z/11/Z) and an ERC Advanced grant (294880) awarded to H.W. and NHMRC grants (project 602516, program 1113133) awarded to J.S. and H.W. or P.B. and A.S., respectively; N.P. is supported by the Swiss National Science Foundation (P300P3_158509), P.B., J.S. and A.S. are supported by NHMRC fellowships (1042629 1107149 and 1020363, respectively). This work is dedicated to the memory of our beloved colleague and friend Dr Martin Leverkus.